EICHORPublic-registry trials using Methotrexate that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Methotrexate appears in 1 registered trial Eichor's radar has found, sponsored by Jeffrey J Crowley MD, the most recent registered as Phase 2 / Phase 3, with a planned enrollment of 56. Registered timeline: 2017–2018. The registry holds 2,534 registered studies for Psoriasis.
| Trial | Sponsor | Condition | Phase | Sites |
| MAP Study: Methotrexate and Adalimumab in Psoriasis | Jeffrey J Crowley MD | Psoriasis | PHASE2 / PHASE3 | 4 |
| Status | Completed · planned start 2017-04 |
| Primary completion | 2018-12 |
| Enrollment target | 56 participants |
| Design | Randomized · Parallel · Phase 2 / Phase 3 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 4 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT03217734.
| First FDA approval | METHOTREXATE SODIUM — December 1953 (application NDA008085, currently held by STRIDES PHARMA INTL) |
| Approved applications | 53 — a multi-source (generic) drug |
| Forms & routes | Injectable, Tablet, Solution · Injection, Oral, Subcutaneous, Intravenous |
| Registry-wide use | 2,342 registered studies all-time · 226 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 2,534 registered studies for Psoriasis. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs
